Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VITX - new IPO with room to grow -- Ignore unavailable to you. Want to Upgrade?

To: Preston Lurie who wrote (32)	2/4/2001 7:30:21 PM
From: Matrix_Man	Respond to of 37

Yes, I still like it. I know they are working on setting up phase three trials. Their competition (CERS) is quite far behind where they seem to be, although they are valued considerably higher - I think because of their partnership with Baxter. The real risk lies in whether or not they can actually bring their product to market in any sizable way once they are FDA approved. They also have partnerships in place which should help. At least I am betting that they will pull it off. What I really like about this company is their technology for removing the blood group antigens, so essentially every unit is a universal donor unit. The greatest risk of blood transfusion is clerical errors and lab errors. This will essentially eliminate that problem.